Literature DB >> 18258412

Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief.

Giovambattista Zeppetella1.   

Abstract

Breakthrough pain is a common and distinct component of cancer pain that is usually managed with normal release opioids (also known as rescue medication) either before or soon after its onset. A prospective survey of hospice inpatients with breakthrough pain was undertaken to characterize their pain and then compare the time to onset of pain relief of their rescue medication. Patients presented with, on average, 1.7 different types of breakthrough pains (range, 1-4). The average number of breakthrough pains was four per day (range, 1-8), and the average duration of breakthrough pain was 35 minutes (range, 15-60); most occurred suddenly and unpredictably. Patients used morphine, oxycodone, hydromorphone, methadone, or oral transmucosal fentanyl citrate as rescue medication and the average time to meaningful pain relief following their administration was 31 minutes (range, 5-75). No difference was found between morphine, oxycodone, and hydromorphone. Methadone appeared to work faster than morphine (P<0.01) but no faster than oxycodone or hydromorphone, whereas oral transmucosal fentanyl citrate worked faster than morphine, oxycodone, hydromorphone, and methadone (P<0.001).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18258412     DOI: 10.1016/j.jpainsymman.2007.06.012

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  19 in total

Review 1.  Substance abuse in cancer pain.

Authors:  Tatiana D Starr; Lauren J Rogak; Steven D Passik
Journal:  Curr Pain Headache Rep       Date:  2010-08

Review 2.  [Cancer breakthrough pain. Indications for rapidly effective opioids].

Authors:  J Kessler; H J Bardenheuer
Journal:  Anaesthesist       Date:  2011-07       Impact factor: 1.041

3.  [Questions from a pain physician reader: Evidence, empiricism, eminence - all the same?].

Authors:  W Meißner; F Petzke; R Sabatowski
Journal:  Schmerz       Date:  2013-08       Impact factor: 1.107

4.  Time to pain relief after immediate-release morphine in episodic pain: the TIME study.

Authors:  Claudio Lo Presti; Alessandro Roscetti; Davide Muriess; Massimo Mammucari
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 5.  Use of hydromorphone, with particular reference to the OROS formulation, in the elderly.

Authors:  David Lussier; Ute Richarz; Gabriele Finco
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

Review 6.  Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group.

Authors:  Sebastiano Mercadante; Paolo Marchetti; Arturo Cuomo; Massimo Mammucari; Augusto Caraceni
Journal:  Support Care Cancer       Date:  2015-10-05       Impact factor: 3.603

7.  Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study.

Authors:  Jordi Guitart; Isabel Vargas; Vicente De Sanctis; Julia Ferreras; Jose Fuentes; Rafael Salazar; Juan M Vázquez; Jordi Folch; Jordi Moya; Hermann Ribera; Francisco Rodelas; Albert Tomás; María Arilla; Joan Coma; Teresa Aberasturi; Dolores Sintes; Ester Lombán
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859

Review 8.  Fentanyl for the treatment of tumor-related breakthrough pain.

Authors:  Helmar Bornemann-Cimenti; Mischa Wejbora; Istvan S Szilagyi; Andreas Sandner-Kiesling
Journal:  Dtsch Arztebl Int       Date:  2013-04-19       Impact factor: 5.594

9.  [Rapid release fentanyl administration forms. Comments of the Working Group on Tumor Pain of the German Pain Society].

Authors:  S Wirz; C H R Wiese; M Zimmermann; U Junker; E Heuser-Grannemann; M Schenk
Journal:  Schmerz       Date:  2013-02       Impact factor: 1.107

Review 10.  Assessment and management of breakthrough pain in cancer patients: current approaches and emerging research.

Authors:  Neil A Hagen; Patricia Biondo; Carla Stiles
Journal:  Curr Pain Headache Rep       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.